Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE.


Journal

Circulation. Cardiovascular quality and outcomes
ISSN: 1941-7705
Titre abrégé: Circ Cardiovasc Qual Outcomes
Pays: United States
ID NLM: 101489148

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 30 5 2020
medline: 22 6 2021
entrez: 30 5 2020
Statut: ppublish

Résumé

Many large-scale cardiovascular clinical trials are plagued with escalating costs and low enrollment. Implementing a computable phenotype, which is a set of executable algorithms, to identify a group of clinical characteristics derivable from electronic health records or administrative claims records, is essential to successful recruitment in large-scale pragmatic clinical trials. This methods paper provides an overview of the development and implementation of a computable phenotype in ADAPTABLE (Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness)-a pragmatic, randomized, open-label clinical trial testing the optimal dose of aspirin for secondary prevention of atherosclerotic cardiovascular disease events. A multidisciplinary team developed and tested the computable phenotype to identify adults ≥18 years of age with a history of atherosclerotic cardiovascular disease without safety concerns around using aspirin and meeting trial eligibility criteria. Using the computable phenotype, investigators identified over 650 000 potentially eligible patients from the 40 participating sites from Patient-Centered Outcomes Research Network-a network of Clinical Data Research Networks, Patient-Powered Research Networks, and Health Plan Research Networks. Leveraging diverse recruitment methods, sites enrolled 15 076 participants from April 2016 to June 2019. During the process of developing and implementing the ADAPTABLE computable phenotype, several key lessons were learned. The accuracy and utility of a computable phenotype are dependent on the quality of the source data, which can be variable even with a common data model. Local validation and modification were required based on site factors, such as recruitment strategies, data quality, and local coding patterns. Sustained collaboration among a diverse team of researchers is needed during computable phenotype development and implementation. The ADAPTABLE computable phenotype served as an efficient method to recruit patients in a multisite pragmatic clinical trial. This process of development and implementation will be informative for future large-scale, pragmatic clinical trials. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02697916.

Sections du résumé

BACKGROUND
Many large-scale cardiovascular clinical trials are plagued with escalating costs and low enrollment. Implementing a computable phenotype, which is a set of executable algorithms, to identify a group of clinical characteristics derivable from electronic health records or administrative claims records, is essential to successful recruitment in large-scale pragmatic clinical trials. This methods paper provides an overview of the development and implementation of a computable phenotype in ADAPTABLE (Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness)-a pragmatic, randomized, open-label clinical trial testing the optimal dose of aspirin for secondary prevention of atherosclerotic cardiovascular disease events.
METHODS AND RESULTS
A multidisciplinary team developed and tested the computable phenotype to identify adults ≥18 years of age with a history of atherosclerotic cardiovascular disease without safety concerns around using aspirin and meeting trial eligibility criteria. Using the computable phenotype, investigators identified over 650 000 potentially eligible patients from the 40 participating sites from Patient-Centered Outcomes Research Network-a network of Clinical Data Research Networks, Patient-Powered Research Networks, and Health Plan Research Networks. Leveraging diverse recruitment methods, sites enrolled 15 076 participants from April 2016 to June 2019. During the process of developing and implementing the ADAPTABLE computable phenotype, several key lessons were learned. The accuracy and utility of a computable phenotype are dependent on the quality of the source data, which can be variable even with a common data model. Local validation and modification were required based on site factors, such as recruitment strategies, data quality, and local coding patterns. Sustained collaboration among a diverse team of researchers is needed during computable phenotype development and implementation.
CONCLUSIONS
The ADAPTABLE computable phenotype served as an efficient method to recruit patients in a multisite pragmatic clinical trial. This process of development and implementation will be informative for future large-scale, pragmatic clinical trials. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02697916.

Identifiants

pubmed: 32466729
doi: 10.1161/CIRCOUTCOMES.119.006292
pmc: PMC7321832
mid: NIHMS1589988
doi:

Substances chimiques

Platelet Aggregation Inhibitors 0
Aspirin R16CO5Y76E

Banques de données

ClinicalTrials.gov
['NCT02697916']

Types de publication

Clinical Trial Protocol Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e006292

Subventions

Organisme : AHRQ HHS
ID : K12 HS026385
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States

Références

J Am Med Inform Assoc. 2013 Jan 1;20(1):144-51
pubmed: 22733976
Contemp Clin Trials Commun. 2018 Mar 09;10:42-49
pubmed: 29696157
Med Care. 2013 Aug;51(8 Suppl 3):S30-7
pubmed: 23774517
Contemp Clin Trials Commun. 2018 Nov 10;12:154-160
pubmed: 30480162
J Am Med Inform Assoc. 2013 Jan 1;20(1):117-21
pubmed: 22955496
J Am Med Inform Assoc. 2013 Dec;20(e2):e226-31
pubmed: 23956018
Am Heart J. 2013 Jun;165(6):837-47
pubmed: 23708153
J Biomed Inform. 2013 Oct;46(5):830-6
pubmed: 23820016
J Am Med Inform Assoc. 2017 Sep 1;24(5):996-1001
pubmed: 28340241
J Biomed Inform. 2004 Jun;37(3):147-61
pubmed: 15196480
Ann Intern Med. 2009 Sep 1;151(5):359-60
pubmed: 19638404
Ann Intern Med. 2015 Oct 20;163(8):635-6
pubmed: 26301537
EGEMS (Wash DC). 2018 Apr 13;6(1):3
pubmed: 29881761
J Am Coll Cardiol. 2016 Oct 25;68(17):1898-1907
pubmed: 27765193
Circulation. 2017 Sep 26;136(13):1207-1216
pubmed: 28687707
J Biomed Inform. 2010 Jun;43(3):451-67
pubmed: 20034594
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:1-8
pubmed: 22262586
Med Care. 2012 Jul;50 Suppl:S21-9
pubmed: 22692254
Artif Intell Med. 2016 Jul;71:57-61
pubmed: 27506131
Int J Qual Health Care. 2012 Jun;24(3):200-5
pubmed: 22490301
EGEMS (Wash DC). 2014 Jul 11;2(1):1079
pubmed: 25848594
Stud Health Technol Inform. 2015;216:574-8
pubmed: 26262116
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:12-7
pubmed: 22262588
N Engl J Med. 2014 Jun 5;370(23):2165-7
pubmed: 24897081
J Am Med Inform Assoc. 2017 Nov 1;24(6):1062-1071
pubmed: 28379377
EGEMS (Wash DC). 2016 Jul 05;4(3):1232
pubmed: 27563686
BMC Med Inform Decis Mak. 2019 Apr 4;19(Suppl 3):78
pubmed: 30943974
J Am Med Inform Assoc. 2013 Dec;20(e2):e206-11
pubmed: 24302669
BMC Med Res Methodol. 2017 Sep 18;17(1):144
pubmed: 28923013
CMAJ Open. 2019 Feb 3;7(1):E23-E32
pubmed: 30718353
Clin Trials. 2010 Apr;7(2):183-9
pubmed: 20338903
BMC Med Inform Decis Mak. 2013 Mar 21;13:37
pubmed: 23514203

Auteurs

Faraz S Ahmad (FS)

Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (F.S.A.).

Iben M Ricket (IM)

Louisiana Public Health Institute, New Orleans (I.M.R.).

Bradley G Hammill (BG)

Duke University School of Medicine, Durham, NC (B.G.H., M.T.R., W.S.J.).
Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., W.S.J.).

Lisa Eskenazi (L)

Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., W.S.J.).

Holly R Robertson (HR)

Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., W.S.J.).

Lesley H Curtis (LH)

Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., W.S.J.).

Cecilia D Dobi (CD)

Department of Clinical Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (C.D.D.).

Saket Girotra (S)

University of Iowa Carver College of Medicine, Iowa City (S.G.).
Iowa City Veteran Affairs Medical Center (S.G.).

Kevin Haynes (K)

Scientific Affairs, HealthCore, Inc., Wilmington, DE (K.H.).

Jorge R Kizer (JR)

Cardiology Section, San Francisco Veterans Affairs Health Care System, CA (J.R.K.).
Department of Medicine and Department of Epidemiology and Biostatistics, University of California San Francisco (J.R.K.).

Sunil Kripalani (S)

Department of Medicine, Vanderbilt University Medical Center, Veterans Health Administration-Tennessee Valley Healthcare System Geriatric Research Education Clinical Center, Health Services Research and Development Center, Nashville, TN (S.K., C.L.R.).

Mathew T Roe (MT)

Duke University School of Medicine, Durham, NC (B.G.H., M.T.R., W.S.J.).
Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., W.S.J.).

Christianne L Roumie (CL)

Department of Medicine, Vanderbilt University Medical Center, Veterans Health Administration-Tennessee Valley Healthcare System Geriatric Research Education Clinical Center, Health Services Research and Development Center, Nashville, TN (S.K., C.L.R.).

Russ Waitman (R)

Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS (R.W.).

W Schuyler Jones (WS)

Duke University School of Medicine, Durham, NC (B.G.H., M.T.R., W.S.J.).
Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., W.S.J.).

Mark G Weiner (MG)

Department of Population Health Sciences, Weill Cornell Medicine, New York Presbyterian-Weill Cornell Campus, New York (M.G.W.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH